lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated adenocarcinoma of the lung
Published 8 years ago • 218 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:14
lux-lung 7: phase 2b trial of first-line afatinib versus gefitinib for egfr mutation-positive nsclc
-
1:21
lux-lung 7: phase 2b trial of afatinib versus gefitinib for egfr-mutated lung cancer in first-line
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
2:15
phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
-
1:59
dr. tolba on the use of afatinib in nrg1-mutated lung adenocarcinoma
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
5:13
gracecast-115_lung-cancer_asco 2012 lc highlights: dr. neal on lux-lung 3 trial for advanced nsclc
-
0:51
dr. tianhong (tina) li reviews the lux-lung 3 trial afatinib data
-
6:57
周處除三害：肺癌用藥觀念的錯誤，看電影學習肺癌 the pig, the snake and the pigeon: lung cancer medication insights
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
48:50
introduction to lung ultrasound
-
0:58
the activity of afatinib in lung cancer
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
4:09
frontline afatinib in egfr-mutant nsclc
-
1:35
afatinib for advanced egfrm-positive nsclc
-
5:43
tolerability-guided dose adjustment of afatinib in nsclc
-
0:17
afatinib inhibits egfr receptor activation
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
10:37
lux-lung 7 head-to-head clinical trial
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:26
elderly patients with egfr-mutated lung cancer: afatinib, gefitinib, erlotinib study | aging-us
-
5:06
gefitinib with chemotherapy does not significantly improve progression-free survival lung cancer